August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Paolo Tarantino: How Will Physicians Translate The Tesults of DESTINY-Breast09 Into Clinical Practice?
Jun 1, 2025, 07:22

Paolo Tarantino: How Will Physicians Translate The Tesults of DESTINY-Breast09 Into Clinical Practice?

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared Community Health Media‘s post on LinkedIn, adding:

“How will physicians translate the results of DESTINY-Breast09 into clinical practice?
Will we treat HER2+ MBC with indefinite T-DXd/P, or stop chemo at a certain point?
Fun discussion with Jason A. Mouabbi.”

Quoting Community Health Media’s post:

“What happens when HER2-targeted therapies like T-DXd challenge not only clinical expectations, but also the very framework of breast cancer classifications?
Drs. Paolo Tarantino and Jason A. Mouabbi explore how evolving HER2 definitions are reshaping patient care, trial design, and what we consider ‘treatable.’.Their conversation dives into the complexities of HER2-low disease and why precision isn’t just about biomarkers—it’s about mindset.
Watch the full CHM Conversations episode for deeper insight into the shifting landscape of HER2+ breast cancer.”

Proceed to the video attached to the post.

More posts featuring Paolo Tarantino.